Across TCGA pan-cancer cohorts, STARD10 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated STARD10 data layer compared with 26 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher STARD10 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated STARD10 expression acts as an unfavorable survival marker.

LUSC, PRAD, and LIHC are the cancer types where STARD10 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.181	0.776	.004	24	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LIHC	DFS	Median	All	0.100	0.543	.038	6	view →
SKCM	DFS	Median	All	0.192	0.757	.022	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: STARD10 tumor-vs-normal RNA expression · all STARD10 data types